|Basic InformationMore InformationLookupsLatest News|Google Search Trends Suggest Mental Woes Vary by SeasonsU.S. Must Step Up Response to Vets, Report SaysNews Coverage of Shootings May Boost Stigma of Mental IllnessADHD Can Often Persist Into AdulthoodChildhood Bullying Linked to Adult Psychiatric OutcomesShared Genes May Link ADHD, Autism and DepressionMarked Geographic Variation in Mental Health Medication UseSocial Withdrawal, Isolation Should Be Addressed in YoungMental Disorders Linked With Domestic Violence, Study SaysWorkplace Bullying Takes Toll on Witnesses Too, Study FindsADHD Can Cause Lifelong Problems, Study FindsConcerns for Long-Term Safety of Antipsychotics in Over 40sSAMHSA: Prevalence of Mental Illness in U.S. Stable in 2011Psychiatry Gets Revised Diagnostic ManualMental Illness Affects 1 in 5 U.S. Adults, Survey FindsLong-Term Use of Some Antipsychotics Not Warranted in Older Adults: StudyFor Many, 'Superstorm' Sandy Could Take Toll on Mental HealthDeployment Affects Mental Health of Relief WorkersPhysical Ailments Take Toll on Mental Health: StudySerious Mental Illness Tied to Higher Cancer, Injury Risk: StudiesAging Boomers' Mental Health Woes Will Swamp Health System: ReportFamily History of Schizophrenia, Bipolar Disorder May Up Kids' Risk for AutismMental Health Woes Raise Odds for Prescription Painkiller AbuseQuestions and AnswersVideosLinksBook Reviews
Concerns for Long-Term Safety of Antipsychotics in Over 40s
Updated: Dec 7th 2012
FRIDAY, Dec. 7 (HealthDay News) -- For patients over the age of 40 with psychosis, treatment with one of the four most commonly used atypical antipsychotic (AAP) drugs (aripiprazole, olanzapine, quetiapine, and risperidone) may lack effectiveness and is associated with a high incidence of side effects, according to a study published online Nov. 27 in the Journal of Clinical Psychiatry.
Hua Jin, M.D., of the University of California in San Diego, and colleagues evaluated the long-term safety and effectiveness of the four most commonly used AAPs. Participants included 332 adults over the age of 40 years with psychosis associated with schizophrenia, mood disorders, posttraumatic stress disorder, or dementia; all were followed for up to two years. An equipoise-stratified randomization method was used to allow physicians or patients to exclude study drugs based on past experience or anticipated risk.
The researchers found that there were no significant differences in metabolic parameters or most other outcome measures between the groups. There was a high rate of discontinuation and many experienced a lack of significant improvement in psychopathology. The incidence of metabolic syndrome was 36.5 percent in one year, and the cumulative incidence of adverse events was also high for all AAPs (serious, 23.7 percent; non-serious, 50.8 percent).
"We found a lack of effectiveness and a high incidence of side effects with four commonly prescribed AAPs across diagnostic groups in patients over age 40, with relatively few differences among the drugs," the authors write. "Caution in the use of these drugs is warranted in middle-aged and older patients."
One author disclosed financial ties to pharmaceutical companies that manufacture the drugs used in this study. Study medications were donated by AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Janssen Scientific Affairs.
Full Text (subscription or payment may be required)
This article: Copyright © 2012 HealthDay. All rights reserved.